Paul Fatheree

Paul, Senior Vice President of Medicinal Chemistry, joined DICE Therapeutics in October 2018 as Vice President of Medicinal Chemistry in the Early Development group. He has over 25 years of medicinal chemistry experience in roles of increasing leadership and has successfully overseen the chemistry and early CMC activities for multiple research programs. Most recently, Paul was at ViewPoint Therapeutics where he was the Vice President of Chemistry overseeing the discovery and early development of small molecule correctors of misfolded proteins. Prior to ViewPoint Therapeutics, Paul was at Theravance Biopharma as a Senior Director of Chemistry where he was involved in the identification of over 7 differentiated clinical candidates across multiple indications, target classes, and routes of administration including Vibativ® (telavancin), Velusetrag (TD-5108), Cefilavancin (TD-1792), and TD-8236 a novel, inhaled pan-JAK inhibitor.

Prior to Theravance BioPharma, Paul was a chemist at Arris Pharmaceuticals and Syntex Research. Paul holds a B.S. in Chemistry from the University of California, Santa Barbara.